Articles related to GUIDELINES/RECOMMENDATIONS

TFOS DEWS III proposes a driver-based approach to dry eye disease, emphasizing standardized diagnosis, disease subtyping, and layered treatment strategies matched to underlying mechanisms rather than rigid severity-based escalation.

A joint epilepsy society position statement endorsed validated noninvasive seizure detection and alerting devices as part of individualized epilepsy care while emphasizing their strongest performance in tonic-clonic seizures and the absence of proven SUDEP prevention.

A first joint EULAR/PReS guideline unifies systemic juvenile idiopathic arthritis and adult-onset Still’s disease under a single name, Still’s disease, and recommends early IL-1 or IL-6 inhibitor therapy over prolonged glucocorticoid use.

A new Endocrine Society guideline favors watchful waiting over immediate evaluation for many girls with early breast development, narrows brain MRI and genetic testing to select cases, and sets age limits for stopping GnRH agonist therapy.

The American College of Physicians issued a living clinical guideline recommending semaglutide and tirzepatide as first-line pharmacologic treatments with lifestyle modifications for nonpregnant adults with obesity (BMI 30 kg/m2 or higher) or overweight (BMI 27 to 30 kg/m2) with at least one weight-related comorbidity, with phentermine-topiramate, liraglutide, and naltrexone-bupropion designated as second-, third-, and fourth-line options respectively based on GRADE evidence review.

The GINA 2026 update introduces age-stratified primary care flowcharts for asthma exacerbation management, expands biologic guidance including depemokimab, and adds a formal red-flag list for fatal or near-fatal asthma risk in adults and adolescents.